Press Releases

/Press Releases

Bonti Announces Hot Topics Presentation Featuring EB-001 at Plastic Surgery The Meeting

Positive Phase 2 Proof of Concept Clinical Data Paves the Way for Therapeutic Musculoskeletal Pain Management and for Further Facial Aesthetic Studies Bonti, a privately-held, clinical-stage biotechnology company, today announced a Hot Topics presentation featuring proof of concept clinical results for its lead product EB-001 at Plastic Surgery The Meeting on October 6th in Orlando, FL. Dr. Brian Kinney presented [...]

2018-05-03T21:04:13+00:00October 9th, 2017|Press Releases|

Bonti Announces Presentation of EB-001 Clinical Study Results

Poster Highlighting Novel Neurotoxin’s Phase 2a Glabellar Lines Study Data Featured in October in Chicago, IL Bonti, a privately-held, clinical-stage biotechnology company, today announced the presentation of clinical study results for its lead product EB-001 at the American Society for Dermatological Surgery (ASDS) Annual Meeting from October 5th through October 8th in Chicago, IL. A featured poster will highlight topline [...]

2018-05-03T21:05:07+00:00September 13th, 2017|Press Releases|

Bonti Announces Start of LANTERN-1 Phase 2 Clinical Study Evaluating EB-001 in Reducing Musculoskeletal Pain

Interim Data Anticipated by Year-end 2017 Bonti, a privately-held, clinical-stage biotechnology company, today announced the initiation of its LANTERN clinical program aimed at relieving musculoskeletal pain and reducing use of opioids using its neurotoxin platform. The first clinical study, LANTERN-1, one of two Phase 2 clinical studies, is a placebo-controlled, double-blind ascending dose cohort trial to evaluate the safety and [...]

2018-05-03T21:05:35+00:00August 23rd, 2017|Press Releases|

Bonti Announces Topline Results of EB-001 Phase 2A Clinical Study in Glabellar Lines

First Clinical Study with Novel Serotype E Botulinum Toxin Confirmed Favorable Safety and Differentiated Efficacy Profile Bonti, a privately-held, clinical-stage biotechnology company, today announced topline results of the first clinical study of its lead product candidate, EB- 001, in glabellar (frown) lines. The study achieved its objectives and confirmed both favorable safety and the expected clinical efficacy profile. EB-001 is [...]

2018-05-03T21:06:03+00:00August 9th, 2017|Press Releases|

Bonti Announces Company Presentation At Renowned And Popular 2017 BIO International Convention

Fauad Hasan, Co-founder And CEO, To Spotlight Bonti on June 19th In San Diego, CA Bonti, a privately-held, clinical-stage biotechnology company, today announced a corporate presentation by its CEO at the 2017 BIO International Convention in the Business Forum on Monday, June 19th at 4:15 PM (local time) in San Diego, CA. Mr. Hasan will highlight Bonti’s lead product candidate, [...]

2018-05-03T21:06:10+00:00June 14th, 2017|Press Releases|

Bonti Announces Poster Presentation on EB-001 Pharmacological Profile at Abdominal Wall Reconstruction Conference

Lead Product Candidate, A Botulinum Neurotoxin Serotype E (BoNT/E), To Be Featured on June 8th in Washington, DC Bonti, a privately-held, clinical-stage biotechnology company, today announced a poster presentation highlighting the pharmacological profile of its lead molecule, EB-001, a fast-acting botulinum neurotoxin. The poster at the 2017 Abdominal Wall Reconstruction (AWR) Conference, hosted by MedStar Georgetown University Hospital, will show [...]

2018-05-03T21:06:16+00:00June 6th, 2017|Press Releases|

Bonti Announces Hot Topics Presentation of Phase 2a Interim Clinical Data at The Aesthetic Meeting 2017

Investigational Product EB-001 and Co-principal Investigator Dr. Steve Yoelin Spotlighted at Premier Global Session on April 28th in San Diego, CA Bonti, a privately-held, clinical-stage biotechnology company, today announced the debut presentation of interim clinical data from Phase 2 study EB- 001-GL201 of EB-001 in subjects with glabellar (frown) lines. Dr. Steve Yoelin, a co-principal investigator of the study, led [...]

2018-05-03T21:06:26+00:00May 3rd, 2017|Press Releases|

Bonti Announces Inaugural Presentation of Phase 2a Clinical Data for Its Lead Product EB-001

Clinical Investigator Dr. Steve Yoelin is a Featured Hot Topics Speaker at The Aesthetic Meeting 2017 on April 28th in San Diego, CA Bonti, a privately-held, clinical-stage biotechnology company, today announced the inaugural presentation of Phase 2a clinical data for its lead product EB-001 in subjects with glabellar (frown) lines. Dr. Steve Yoelin, a co-principal investigator, will present at the [...]

2018-05-03T21:06:33+00:00April 27th, 2017|Press Releases|

Bonti Raises $11.7 million in an Oversubscribed Series B Financing to Advance Development of Lead Product EB-001

First-in-Human Phase 2a Clinical Proof of Concept Study Already Underway Bonti, a privately-held, clinical-stage biotechnology company, today announced it successfully secured $11.7 million in a Series B financing. Proceeds from the round will be used to continue developing EB-001, a unique botulinum neurotoxin, for its targeted aesthetic and therapeutic indications with multi-billion dollar addressable market opportunities. In 2015, Bonti completed [...]

2018-05-03T21:06:39+00:00April 18th, 2017|Press Releases|

Bonti Raises $ 11.7 million in an Oversubscribed Series B Financing

Bonti, a privately-held, clinical-stage biotechnology company, today announced it successfully secured $11.7 million in a Series B financing. Proceeds from the round will be used to continue developing EB-001, a unique botulinum neurotoxin, for its targeted aesthetic and therapeutic indications with multi-billion dollar addressable market opportunities. In 2015, Bonti completed an $8.9 million Series A financing, bringing the total cumulative [...]

2018-05-03T21:06:51+00:00April 18th, 2017|Press Releases|